Clinical trial
Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation…
NCT00153881 · Dartmouth-Hitchcock Medical Center, Other · Completed
Key facts
| NCT number | NCT00153881 |
|---|---|
| Title | Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer |
| Official title | Docetaxel and Carboplatin Followed by a Dose-Ranging Study of Oral Capecitabine, Weekly Docetaxel, and Concomitant External Beam Radiotherapy for the Treatment of Patients With Stage II-III Carcinoma of the Esophagus and Gastro-Esophageal Junction |
| Lead sponsor | Dartmouth-Hitchcock Medical Center, Other |
| Collaborators | Sanofi Industry Hoffmann-La Roche |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Esophageal Neoplasms |
| Intervention type | Drug |
| Interventions | Capecitabine (Xeloda) |
| Enrollment | 44 |
| Start date | Feb 1, 2000 |
| Primary completion | Sep 1, 2013 |
| Completion | Sep 1, 2013 |
| First posted | Sep 12, 2005 |
| Last update posted | Nov 13, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: